Home>Topics>Companies>Bristol-Myers Squibb

Bristol-Myers Squibb BMY

  1. All
  2. Commentary
  3. Headlines
    1. Bristol - Myers to present oncology data at the end of the month

      Headlines

      Sun, 19 Oct 2014

      Bristol - Myers Squibb (NYSE: BMY ) will hold a teleconference on Friday, October 31 at 1:30 pm CT/2:30 pm ET to review data presented at the Chicago Multidisciplinary

    2. Cramer's Mad Money - 13 Earnings To Watch In The Week Ahead (10/17/14)

      Headlines

      Sun, 19 Oct 2014

      3M (NYSE: MMM ), Amazon (NASDAQ: AMZN ) Caterpillar (NYSE: CAT ), Procter & Gamble (NYSE: PG ), Bristol Myers (NYSE: BMY ). Other stocks mentioned: Alibaba (NYSE: BABA ), Vodafone (NASDAQ: VOD ), First Solar (NASDAQ: FSLR

    3. Members of Big Pharma to square off at breast cancer meeting

      Headlines

      Fri, 17 Oct 2014

      s product, Keytruda (pembrolizumab) injection, is currently cleared for the treatment of melanoma. Bristol - Myers Squibb (NYSE: BMY ) and AstraZeneca (NYSE: AZN ) are also players in the space. 1 comment!

    4. Bristol - Myers establishes clinical trial collaboration in blood cancers

      Headlines

      Mon, 13 Oct 2014

      Bristol - Myers Squibb (NYSE: BMY ), Pharmacyclics (NASDAQ: PCYC ) and Janssen Research & Development ..... to evaluate the safety, tolerability and preliminary efficacy of BMY 's Opdivo ( nivolumab ) in combination with Imbruvica (ibrutinib

    5. Portola's New Factor Xa Antidote Could Help Drive Xarelto And Eliquis Sales

      Headlines

      Thu, 9 Oct 2014

      Ingelheim. Then came Xarelto by Johnson & Johnson (NYSE: JNJ ). Finally, Pfizer (NYSE: PFE ) and Bristol - Myers Squibb (NYSE: BMY ) teamed up to release Eliquis. While these drugs are more convenient and have less interactions then Coumadin

    6. Called Strike 3 For Bristol-Myers Squibb : What This Says For Gilead And Its Competitors In The Hep C Market

      Headlines

      Wed, 8 Oct 2014

      By Pharma Doc : Background: The hepatitis C landscape is an extremely competitive area for pharmaceuticals and biotechs. Years ago, the standard of care for HCV genotype 1 patients was Pegasys and Ribavirin for 48 weeks of treatment. Side effects were very bad (nausea and flu-like symptoms), and ...

    7. Bristol - Myers resolves efavirenz patent litigation

      Headlines

      Wed, 8 Oct 2014

      Bristol - Myers Squibb (NYSE: BMY ) resolves all outstanding U.S. patent litigation related to efavirenz , an active ingredient in Sustiva (efavirenz) and Atripla

    8. UPDATE 2- Bristol - Myers pulls U.S. marketing application for hep C treatment

      Headlines

      Tue, 7 Oct 2014

      (Adds comment from Bristol - Myers and analyst, adds background, updates shares)

    9. Bristol - Myers pulls U.S. marketing application for hepatitis C treatment

      Headlines

      Tue, 7 Oct 2014

      Oct 7 (Reuters) - Bristol - Myers Squibb said it withdrew its U.S. marketing application for a drug combination to treat hepatitis C.

    10. Bristol - Myers pulls hep C NDA

      Headlines

      Tue, 7 Oct 2014

      rapidly evolving hepatitis C treatment landscape," Bristol - Myers Squibb (NYSE: BMY ) decides not to pursue U.S. regulatory approval ..... daclatasvir, a pan-genotypic NS5A complex inhibitor . BMY developed the dual regimen to meet the distinct needs

    « Prev12345Next »
    Content Partners